NL-OMON44302已完成2 期
Double-blinded, randomised, placebo-controlled, multicentre , Phase IIa study to investigate the effect, safety and tolerability of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together with safety and tolerability, in subjects with elevated lipoprotein a (Lp[a ]) - ATH-3G10-005
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
入选标准
- •1. Provision of a signed written informed consent
- •2. Lp(a) above 50 mg/dL at screening
- •3. Male or female, >= 50 years of age at screening
排除标准
- •1. History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the result or the subject*s ability to participate in the study
- •2. Illness (including common colds) for the last 4 weeks before screening
- •3. Medical history of myocardial infarction (MI) or stroke within 12 months of screening
- •4. Ongoing or paroxysmal atrial fibrillation
- •5. Clinically overt heart failure
- •6. Hypertension defined as >=180/100 mmHg
- •7. Diabetes mellitus
研究者
相似试验
进行中（未招募）
1 期
Double-blinded, randomised, placebo-controlled, multicentre , Phase IIa study to investigate the effect efficacy, safety and tolerability of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together with safety and tolerability, in subjects with elevated lipoprotein a (Lp[a ])Arterial inflammation in subjects with elevated lipoprotein a (Lp[a])MedDRA version: 20.0 Level: LLT Classification code 10051615 Term: Atherosclerotic cardiovascular disease System Organ Class: 100000004866EUCTR2017-002106-13-NLAthera Biotechnologies AB40
进行中（未招募）
1 期
Double-blinded, randomised, placebo-controlled, multicentre , Phase IIa study to investigate the effect efficacy, safety and tolerability of phosphorylcholine human monoclonal antibody (PC-mAb) 3G10 on arterial inflammation, together with safety and tolerability, in subjects with elevated lipoprotein a (Lp[a ])Arterial inflammation in subjects with elevated lipoprotein a (Lp[a])MedDRA version: 20.0Level: LLTClassification code 10051615Term: Atherosclerotic cardiovascular diseaseSystem Organ Class: 100000022953EUCTR2017-002106-13-SEAthera Biotechnologies AB40
进行中（未招募）
1 期
Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study on the efficacy and tolerability of budesonide capsules versus placebo for maintenance of remission in patients with collagenous colitis - SOIBD Collagenous Colitis Maintenance Study (SCCMS)Collagenous colitisMedDRA version: 8.1 Level: LLT Classification code 10048928 Term: Colitis collagenousEUCTR2007-001315-31-BEDr. Falk Pharma GmbH92
进行中（未招募）
不适用
Double-blind, randomised, placebo-controlled, multi-centre phase III clinical study comparing the combination of ursodeoxycholic acid capsules plus budesonide capsules to ursodeoxycholic acid capsules plus placebo in the treatment of primary biliary cirrhosis - Ursodeoxycholic acid plus budesonide vs. ursodeoxycholic acid alone in PBCPatients with Primary Biliary Cirrhosis at risk of disease progressionMedDRA version: 9.1Level: LLTClassification code 10036680Term: Primary biliary cirrhosisEUCTR2007-004040-70-ATDr. Falk Pharma GmbH183
进行中（未招募）
1 期
Study to compare the combination of ursodeoxycholic acid andbudesonide with the combination of ursodeoxycholic acid and placebo inthe treatment of primary biliary cirrhosisPBC patients with an incomplete response to UDCA treatment defined by the failure to achieve s-AP levels < 1.5x upper limit of normal after at least 6 months of treatment with UDCA and with inflammatory activity in the histological assessment of the liverMedDRA version: 17.0Level: LLTClassification code 10036680Term: Primary biliary cirrhosisSystem Organ Class: 100000004871EUCTR2007-004040-70-SEDr. Falk Pharma GmbH144